1246261-58-4

Upstream product

• 40137-11-9 diethyl methylsulfonylmethylphosphonate 
• 1246261-48-2 C₂₁H₃₀N₂O₆ 
• 1149-26-4 (S)-N-(benzyloxycarbonyl)valine 
• 153287-86-6 (3S)-3-[(tert-butoxycarbonyl)amino]-4-hydroxybutanoic acid tert-butyl ester 
• 50715-50-9 O¹-(2,5-dioxopyrrolidin-1-yl)-O⁴-tert-butyl-(2S)-2-(tert-butoxycarbonylamino)-butanedioate 
• 153248-79-4 N-α-(tert-butoxycarbonyl)-β-tert-butyl-L-aspartal 

Downstream Products

• 1246261-43-7 C₁₉H₂₆N₂O₇S 

Relevant academic research and scientific papers

Selective caspase inhibitors and uses thereof

The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).

Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. A structure-activity study

The first structure-activity relationship study of vinyl sulfones as caspase-3 inhibitors is reported. A series of 12 vinyl sulfones was synthesized and evaluated for two downstream caspases (caspases-3 and -7). Dipeptidyl derivatives were significantly superior to their counterparts containing only Asp at P1, as caspase-3 inhibitors. Fmoc-Val-Asp-trans-CHCH-SO 2Me was the most potent inhibitor of caspase-3 in the series, with a IC50 of 29 μM and a second-order rate constant of inactivation, kinact/Ki, of 1.5 M-1 s-1. Computational studies suggest that the second amino acid occupies position S3 of the enzyme. In addition, Fmoc-Val-Asp-trans-CHCH-SO 2Ph was inactive for caspase-7 for the tested concentrations. The first structure-activity relationship study of vinyl sulfones as caspase-3 inhibitors is reported. A series of 12 vinyl sulfones was synthesized and evaluated for caspase-3 inhibition.